Timothy A. Springer, PhD is the Latham Family Professor at Harvard Medical School and Boston Children’s Hospital. A world leader in structural biology and immunology, he is also a founder and private investor in ventures including LeukoSite, Scholar Rock, Morphic Therapeutic, Moderna Therapeutic, Editas Medicine, Selecta Biosciences and Ab Initio Biotherapeutics. His research and entrepreneurship has to six FDA-approved drugs.
Steven C. Almo, PhD
Steven C. Almo, PhD, is Professor and Chair of the Department of Biochemistry and Professor of Physiology & Biophysics at Albert Einstein College of Medicine. He is an internationally recognized leader in the field of structural biology and immunology. His lab has been at the center of advancing high-throughput methods for expressing proteins, determining their structure and interrogating their function, as well as developing innovative receptor-ligand de-orphaning platforms. Steve is also a Co-Founder and Chair of the Scientific Advisory Board of Cue Biopharma.
Jeffrey Flier, MD
Jeffrey Flier, MD is the Higginson Professor of Physiology and Medicine at Harvard Medical School and a leading authority in the molecular causes of obesity and diabetes. Dr. Flier served as the 21st Dean of the Faculty of Medicine at Harvard University, and he serves on the boards of several nonprofits including Brandeis University and companies including Scholar Rock.
Maykin Ho, PhD
Maykin Ho, PhD retired as Partner of Goldman Sachs & Co. after 24 years, which included serving as Advisory Director of Global Healthcare Investment Banking and co-head of US Healthcare for Global Investment Research. She is a venture partner of Qiming Venture Partners and serves on the board of directors for Agios Pharmaceuticals, Parexel International, and the Aaron Diamond AIDS Research Center.
Amir Nashat, PhD
Amir Nashat, PhD is a Managing Partner at Polaris Partners and focuses on investments in healthcare. He currently represents Polaris as a Director of eight biotechnology startup companies and has served as a Director of seven others. He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”
Mike O’Hara is a partner at Deloitte and leads its New England life sciences audit practice. He has extensive experience working in the healthcare industry and serves many private and public life sciences companies. Mike has been involved in many IPOs; mergers and acquisitions engagements; financial forecasting projects; and value-added projects related to accounting and financial reporting. He has also assisted his clients through product launches and rapid growth phases, including advising on financial and operational infrastructure challenges. In addition to his role as board member for IPI, Mike is the Treasurer of the Massachusetts Biotechnology Council and an adjunct professor at Boston College.
Samantha Singer is an Entrepreneur in Residence at Third Rock Ventures. She previously served as the Chief Operating Officer of the Broad Institute and, before that, was an executive at Biogen. Singer also served as an Independent Director on the Board for Rodin Therapeutics until the company was acquired by Alkermes.
Scientific Advisory Board
David Baker, PhD
Professor of Biochemistry at University of Washington and Investigator of Howard Hughes Medical Institute. Professor of Biochemistry at University of Washington and Investigator of Howard Hughes Medical Institute.
Stephen Blacklow, MD, PhD
Gustavus Adolphus Pfeiffer Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.
Shuqi Chen, PhD
Founder, former CEO, and former Chairman of the Board of IQuum, Inc. and Former Vice President, Research and Development of Point of Care at Roche Molecular System.
George Church, PhD
Founding Faculty & Synthetic Biology Lead at the Wyss Institute, Robert Winthrop Professor of Genetics at Harvard Medical School, and Professor of Health Sciences & Technology at Harvard and MIT.
Richard Cummings, PhD
Director of the National Center for Functional Glycomics and Professor of Surgery at Beth Israel Deaconess Medical Center & Harvard Medical School.
Eric Fischer, PhD
Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute.
K. Christopher Garcia, PhD
Professor of Molecular and Cellular Physiology and of Structural Biology at Stanford University School of Medicine and Investigator at the Howard Hughes Medical Institute.
Principal at Atlas Venture.
Stephen Harrison, PhD
Giovanni Armenise-Harvard Professor of Basic Medical Sciences, Harvard Medical School and Boston Children’s Hospital, and Investigator in the Howard Hughes Medical Institute.
John Hastewell, DPhil
Former Head of the Novartis Institutes for BioMedical Research Biologics Center (NBC).
Brian Kobilka, MD
Professor of Molecular and Cellular Physiology, and Hélène Irwin Fagan Chair in Cardiology at Stanford University School of Medicine.
Nilesh Kumar, MBA, PhD
Partner at Novo Ventures (US), Inc.
Judy Lieberman, MD, PhD
Chair of the Program in Cellular and Molecular Medicine at Boston Children’s Hospital and Professor of Pediatrics at Harvard Medical School.
Harvey F. Lodish, PhD
Professor of Biology and of Biological Engineering at MIT and founding member of the Whitehead Institute for Biomedical Research. Co-founder of Genzyme, Arris Pharmaceuticals, Millennium Pharmaceuticals, and Rubius.
Deborah Marks, PhD
Associate Professor of Systems Biology and Director of the Raymond and Beverly Sackler Laboratory at Harvard Medical School.
Chief Scientific Officer, Revitope Oncology. Former Vice President of Biologics Drug Discovery at Biogen.
Timothy Mitchison, PhD
Hasib Sabbagh Professor of Systems Biology at Harvard Medical School.
Saurabh Saha, MD, PhD
Senior Vice President R&D and Global Head of Translational Medicine at Bristol-Myers Squibb.
Arlene Sharpe, MD, PhD
George Fabyan Professor of Comparative Pathology and Interim Co-Chair, Microbiology and Immunobiology at Harvard Medical School.
Co-Director, Evergrande Center for Immunologic Diseases at Brigham and Women’s Hospital and Harvard Medical School.
Will Somers, PhD
Vice President of Global Biotherapeutic Technologies at Pfizer.
Ulrich von Andrian, MD, PhD
Mallinckrodt Professor of Immunopathology at Harvard Medical School.
Christopher Walsh, MD, PhD
Chief, Division of Genetics at Boston Childrens Hospital, Bullard Professor of Pediatrics and Neurology at Harvard Medical School.
Leonard I. Zon, MD
Grousbeck Professor of Pediatric Medicine at Harvard Medical School, Investigator at Howard Hughes Medical Institute, Director of the Stem Cell Program, Children’s Hospital Boston, and Co-founder of Scholar Rock.